2005
DOI: 10.4143/crt.2005.37.1.44
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
3
0
4

Year Published

2006
2006
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 13 publications
0
3
0
4
Order By: Relevance
“…Hence, the combination of a cytotoxic agent with BCG could possibly contribute to enhanced binding, which in turn might explain the 100% tumour‐free survival in the present patients receiving combined therapy of BCG with a cytotoxic agent. Comparative studies on different dosages of mitomycin‐C, thiotepa and epirubicin reported no difference in recurrence rate, dose‐dependent response and concentration‐dependent response [26,27]. Further, there is no standard treatment duration or dose of these agents, and different groups have adopted different dosage schedules.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Hence, the combination of a cytotoxic agent with BCG could possibly contribute to enhanced binding, which in turn might explain the 100% tumour‐free survival in the present patients receiving combined therapy of BCG with a cytotoxic agent. Comparative studies on different dosages of mitomycin‐C, thiotepa and epirubicin reported no difference in recurrence rate, dose‐dependent response and concentration‐dependent response [26,27]. Further, there is no standard treatment duration or dose of these agents, and different groups have adopted different dosage schedules.…”
Section: Discussionmentioning
confidence: 99%
“…However, no consensus on the optimum dosage was reached. When 30 mg and 40 mg instillations were compared there was little difference in recurrence‐free rates [26]; the recurrence rates reported for mitomycin‐C after 1.5 years of follow‐up were 19% and 24% in the 30‐mg group, and 12% and 24% in the 40‐mg group.…”
Section: Discussionmentioning
confidence: 99%
“…[1][2][3]11 Pemberian obat intravesika yang banyak digunakan adalah mitomycin C (MMC), doxorubicin, dan Bacillus Calmette-Guerin (BCG). 1,2,16 Pemberian BCG intravesika bersifat imunoterapi dengan menekan rekurensi serta progresifitas dari karsinoma kandung kemih sehingga diindikasikan untuk penderita-penderita yang cenderung mengalami kekambuhan setelah operasi reseksi transuretral. 1,12,16 BCG mengurangi kekambuhan 40% -45%, dibanding obat intravesika lain yang hanya sebesar 8-18%.…”
Section: Gambar 2 Gambaran Ultrasonografi Yang Menunjukkan Suatu Polunclassified
“…1,2,16 Pemberian BCG intravesika bersifat imunoterapi dengan menekan rekurensi serta progresifitas dari karsinoma kandung kemih sehingga diindikasikan untuk penderita-penderita yang cenderung mengalami kekambuhan setelah operasi reseksi transuretral. 1,12,16 BCG mengurangi kekambuhan 40% -45%, dibanding obat intravesika lain yang hanya sebesar 8-18%. 2,16 Pada beberapa penelitian penggunaan MMC dosis minimal sebagai kemoterapi intravesika telah menunjukkan efektifitas yang sangat tinggi terhadap karsinoma kandung kemih.…”
Section: Gambar 2 Gambaran Ultrasonografi Yang Menunjukkan Suatu Polunclassified
See 1 more Smart Citation